Report initial clinical trial data for BEAM-201
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 8 Nov 2023
- Due
- 31 Dec 2024
- Checked
- 2 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the company expects to report initial data in 2024.”
What we found
Evidence strength A What the grades mean
The provided SEC filings do not contain any information regarding the reporting of initial clinical trial data for BEAM-201, nor do they confirm that such data was reported by the 2024 deadline.
-
A Beam Therapeutics Inc. 10-K filed 2026-02-24
“We are evaluating BEAM-301 in a Phase 1/2 clinical trial, and expect to report initial clinical data in 2026.” ✓ confirmed on the page
Checked 2 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +730 days
- 2 versions
-
Version 1 · original · stated 8 Nov 2023
Deadline 31 Dec 2024 (“in 2024”) · wording expected
-
Version 2 · stated 12 Jan 2026
Deadline 31 Dec 2026 (“in 2026”) · wording expected
“Beam expects to report initial clinical data in 2026.”
-
Version 3 · stated 12 Jan 2026
Deadline 31 Mar 2026 (“end of first quarter 2026”) · wording expected
“Updated clinical data across all cohorts expected by end of first quarter 2026”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- BEAM-201 clinical data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: disagreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and read it as “no_evidence”, so a person decides.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Beam Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-BEAM-003257 · Corrections policy